SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We're responsible for the development of innovative next-generation drugs within SK Group. SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do. With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing. For more information, visit our website at www.skbp.com.
我們正在追蹤 SK Biopharmaceuticals 的市場擴張
過去 90 日內有 2 個訊號。
SK Biopharmaceuticals 的國際擴張與競爭對手的比較
SK Biopharmaceuticals你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 SK Biopharmaceuticals你 | 0 | 0 | — | 0 | 0 |
RPT Business Development Manager
查看招聘Gyeonggi, South Korea · 3星期前
Legal Counsel
查看招聘Gyeonggi, South Korea · 3星期前
경영기획(Corp.Planning Manager)
查看招聘Gyeonggi, South Korea · 2個月前
暫無已追蹤技術
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
SK生物製藥在新澤西州開設「SK Life Science LinX」,為韓國生物科技公司進入美國市場提供160坪設施,包括辦公室和會議室。
SK生物製藥的癲癇藥物Cenobamate和睡眠障礙藥物Solriamfetol獲得中國NMPA批准，進軍中國市場。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 SK Biopharmaceuticals 業務、市場及增長訊號的快速解答。
